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Abstract
The antigen-binding site of Herceptin, an anti-human Epidermal Growth Factor Receptor 2 (HER2) antibody, was engineered
to add a second specificity toward Vascular Endothelial Growth Factor (VEGF) to create a high affinity two-in-one antibody
bH1. Crystal structures of bH1 in complex with either antigen showed that, in comparison to Herceptin, this antibody
exhibited greater conformational variability, also called ‘‘structural plasticity’’. Here, we analyzed the biophysical and
thermodynamic properties of the dual specific variants of Herceptin to understand how a single antibody binds two
unrelated protein antigens. We showed that while bH1 and the affinity-improved bH1-44, in particular, maintained many
properties of Herceptin including binding affinity, kinetics and the use of residues for antigen recognition, they differed in
the binding thermodynamics. The interactions of bH1 and its variants with both antigens were characterized by large
favorable entropy changes whereas the Herceptin/HER2 interaction involved a large favorable enthalpy change. By
dissecting the total entropy change and the energy barrier for dual interaction, we determined that the significant structural
plasticity of the bH1 antibodies demanded by the dual specificity did not translate into the expected increase of entropic
penalty relative to Herceptin. Clearly, dual antigen recognition of the Herceptin variants involves divergent antibody
conformations of nearly equivalent energetic states. Hence, increasing the structural plasticity of an antigen-binding site
without increasing the entropic cost may play a role for antibodies to evolve multi-specificity. Our report represents the first
comprehensive biophysical analysis of a high affinity dual specific antibody binding two unrelated protein antigens,
furthering our understanding of the thermodynamics that drive the vast antigen recognition capacity of the antibody
repertoire.
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Introduction
Monoclonal antibodies are typically specific toward single
antigens. The exquisite specificity of antibody-antigen interactions
is one main reason behind the success of antibodies as targeted
therapeutics [1]. However, there is increasing appreciation for the
prevalence of polyreactive or multispecific antibodies and their
potential roles in the immune recognition function of the antibody
repertoire [2,3,4,5]. Polyreactivity is in fact a common phenom-
enon among the precursors of antibodies on pre or pro B
lymphocytes and is often associated with self reactivity. Although
the receptor editing process eliminates many of these self and
polyreactive clones [6,7], mature B cells that secrete polyreactive
antibodies in the periphery have been reported [2,5,8]. The
finding that antibodies may become polyreactive through somatic
mutations further implicates the prevalence of polyreactive
antibodies in the antibody repertoire [9,10]. The ability of single
antibodies to interact with more than one antigen has been
proposed to expand the effective size of the antibody repertoire,
which theoretically is restricted by the limited number of B
lymphocytes, each expressing only one antibody [4,9,11,12].
Moreover, there is interest in antibodies that may target more than
one antigen molecule for therapeutic applications.
Many have endeavored to understand the molecular
mechanisms of antibody polyreactivity or multi-specificity. Anti-
bodies have been shown to bind distinct antigens that are
conserved chemically and/or structurally with high affinity
[13,14,15,16,17,18,19,20]. However, a single antibody able to
interact with more than one antigen epitope devoid of homology
may have greater impact on the antigen recognition capacity of
the immune repertoire. The multi-specific interactions of antibod-
ies have been studied primarily by first identifying the additional
‘‘antigens’’ toward the antibody of interest from combinatorial
libraries of peptides, small molecules or proteins [4,12,13]. Some
antibodies were shown to rely on conformational variability, or
structural plasticity of the antigen-binding site to adapt to distinct
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e17887antigens [4]. Other antibodies were shown to utilize different
regions of the antigen-binding site to engage various antigens
without involving significant structural plasticity [12,13,19,21].
However, since these polyreactive antibodies derived their
secondary antigens from repertoire selection, the identity of the
secondary antigen cannot be pre-determined. Further, the binding
affinities for the selected secondary antigens are often quite weak.
Insights into the mechanism of high affinity, multi-specific
antibody interactions are still lacking.
We recently described a strategy to generate dual specific
antibodies, or two-in-one antibodies, toward two defined antigens
de novo by recruiting a second specificity to the antigen binding
site of a monospecific antibody [22]. We demonstrated the
strategy by first constructing a combinatorial phage-displayed
library randomizing the light chain (LC) complementarity
determining regions (CDRs) of HerceptinH (trastuzumab), a
humanized antibody originally derived from mouse hybridoma.
From this library, we isolated many variants that can bind a
secondary antigen while maintaining binding towards their
primary antigen HER2. We believe the strategy can be applied
to evolve the specificity of other antibodies because, like
Herceptin, many natural antibodies utilize the heavy chain
(HC) CDRs as the main antigen binding determinants, and
therefore can tolerate some mutation in the LC CDRs. The
sequences of the derived dual specific antibodies demonstrate that
a variety of limited mutations are sufficient for antibodies to
recruit a second specificity. The dual specific antibody bH1 and
its affinity-improved variants represent the first such antibodies
that bind tightly to two unrelated protein antigens, HER2, the
primary antigen, and VEGF, the secondary antigen (Table 1)
[22].
The crystal structures of bH1 in complex with HER2 and
VEGF reveal that bH1 makes contact with its two antigens via a
similar set of surface residues [22]. However, the surface contour
of bH1 buried in either complex is compatible only with the
antigen in complex and molecular acrobatics is clearly involved for
the antibody to bind its two antigens (Figure 1, Figure S1). In
contrast, Herceptin Fab exhibits minimal structural variability
based on the available structures of free and HER2-bound
Herceptin Fab [23,24] (Figure S2).
To understand the dual antigen recognition of these antibodies
evolved from a monospecific antibody and the effect of significant
structural plasticity on binding energetics, here we analyzed the
biophysical and thermodynamic properties of the antigen
interaction of bH1 and its affinity-improved variants including
bH1-44 and compared to those of Herceptin. While bH1 and
bH1-44 share many characteristics with their parent antibody
Herceptin (binding epitopes, affinity, kinetics, and critical CDR
residues), the thermodynamic profile of the dual specific variants
deviate from that of Herceptin. Notably, the bH1 interactions
with HER2 and VEGF were characterized by large favorable
entropy changes whereas the Herceptin interaction was enthalpi-
cally driven. We dissected the total entropy changes to examine
the contribution of the hydrophobic effect (desolvation entropy)
to the antigen interaction and the penalty from reduction of
conformational freedom (conformational entropy) upon antigen
binding. We also examined the accessibility of bH1-44 for
binding its two antigens compared to that of Herceptin for
HER2. We determined that the increased structural plasticity of
bH1 antibodies relative to Herceptin appeared not to negatively
impact the binding free energy. Central to the high dual affinity
of the bH1 antibodies is the structural plasticity, with low
energetic cost, in addition to the hydrophobic desolvation energy
that drives the interactions.
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The affinity-improved HER2/VEGF dual-specific antibody
retains similar binding affinity and kinetics as Herceptin
We determined the binding kinetics for variants of the dual-
specific antibody bH1 and Herceptin as Fabs to immobilized
VEGF (the receptor binding domain, VEGF8–109) or HER2 (the
extracellular domain, ECD, of HER2) using surface plasmon
resonance (SPR) measurements (Figure 2). The bH1 Fab/VEGF
interaction is characterized by a moderate rate of association
(kon=4 610
4 M
21 s
21) and a fast rate of dissociation (koff=
0.01 s
21)a t3 0 uC, which results in a dissociation constant (KD)
of 300 nM. The bH1/HER2 interaction (KD=20 nM, kon=
1610
5 M
21 s
21,k off=2 610
23 s
21) is 40-fold weaker than
the Herceptin Fab/HER2 interaction (KD=0.5 nM, kon=
7610
5 M
21 s
21,k off=4 610
24 s
21 at 30uC). Using two consec-
utive rounds of affinity improvements, bH1 was improved first to
bH1-81 then to bH1-44 with incremental improvements in both
on-rates and off-rates for VEGF and HER2 interactions compared
to the parent bH1 (Figure 2). As a result, bH1-44 binds HER2
with similar affinity and kinetics as Herceptin.
Many interactions between Herceptin and HER2 are
retained in the dual interaction
Alanine-scanning mutagenesis studies of bH1 and bH1-44 [22]
and Herceptin [25] identified the CDR residues that significantly
contribute to the binding free energy (DG). Hotspot residues are
referred to sites where alanine substitution results in a reduction of
10% or greater of the total DG. Analysis of the mutagenesis
mapping shows that bH1 and bH1-44 have conserved all but one of
the Herceptin/HER2 hotspot residues in their sequences. Further,
the majority of Herceptin’s hotspot residues remain important for
both bH1 and bH1-44 to bind HER2 (Figure 3A)( Table 1).
The VEGF binding hotspot contains a different set of residues
when compared to the HER2 hotspot, however, there are five
mostly centrally located CDR residues that contribute significantly
to all three high-affinity Herceptin/HER2, bH1-44/HER2 and
bH1-44/VEGF interactions. This includes two residues in the
light chain (LC; His91 and Tyr92) and three in the heavy chain
(HC; Tyr56, Trp95 and Tyr100a). While the main chain of these
residues are at a similar position in both bH1 structures as in the
Herceptin structures, their side chains appear to undergo various
extents of adjustments in order to optimize interaction with the
two antigens (Figure 1, Figure S1). In particular, Tyr56 of
CDR-H2 exhibits a significant difference in conformation. The
rearrangement of this residue is important since the unique side
chain conformation in the VEGF-bound bH1 is not compatible
for both bH1 and Herceptin to bind HER2. Therefore, the VEGF
binding ability of bH1 appears to co-opt some of the HER2
binding residues of Herceptin, albeit with conformational
adjustments.
bH1-44 largely conserves the hotspot residues of bH1
Nine out of ten VEGF hotspot residues and eight out of nine
HER2 hotspot residues of bH1 are also hotspot residues for bH1-
44 (Figure 3). Further, most of the mutations that distinguish bH1
from bH1-44 involve conservative changes in amino acid residues
located at the periphery of the bH1 hotspots that are not in direct
contact with either antigen based on the bH1 complex structures
(Figure 3B). The conservation of both hotspot and periphery
residues suggests that the molecular structure of the bH1-44
complexes should be similar to that of bH1, with the affinity-
improving mutations likely playing indirect or allosteric roles.
Moreover, residues of CDR-L1, which exhibits highly distinct
conformations in the two bH1-complexes, are similarly important
for both antibodies. The severe effect of mutating Tyr32 of CDR-
Figure 1. The distinct CDR conformations of bH1. The three HC CDRs (cyan) and three LC CDRs (yellow) of bH1 in complex with HER2 (PDB
code 3BE1) or VEGF (PDB code 3BDY) are shown in cartoon representation with the rest of bH1 structure as surface. Selected residues are shown in
stick representation: LC-I29, Y32 and I30c are specifically important for bH1-44/VEGF binding and HC-R50 and R58 are specifically important for bH1-
44/HER2 binding whereas LC-H91 and Y92, and HC-Y56, W95 and Y100a (in bold) are residues important for the bH1-44 interaction with both
antigens as well as the Herceptin interaction with HER2. Note the highly distinct conformations of CDR-L1, the adjustment of the side chains of
highlighted residues, and the side chains of LC-I30c and LC-Y32 that alternatively occupy the nearby cavity (*) in HER2 bound bH1 or VEGF bound
bH1, respectively. See Figure S1 movie (Movie S1) morphing the two structures, which highlights the extent of the conformational adjustment for
dual interaction.
doi:10.1371/journal.pone.0017887.g001
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VEGF binding is striking and demonstrates the importance of
CDR-L1 conformation for both bH1 and bH1-44 to bind VEGF
(Figure 2, Figure S3) [22]. Based on the mutagenesis mapping of
bH1 and bH1-44, we generated Ile29A+Tyr32A (LC) or
Arg50A+Arg58A (HC) mutations in bH1-44, which completely
disrupted the binding to VEGF or HER2, respectively while
maintaining the binding affinity and kinetics for the other antigen
(Figure 2). We also confirmed that the Arg50A+Arg58A (HC)
mutations disrupted Herceptin’s binding to HER2 completely
(Figure S4), which corroborates that bH1-44, much like bH1,
maintains the HER2 interaction of Herceptin. Hence, the
approximately 100-fold improvement of dual affinity (from
20 nM to 0.2 nM in KD for HER2, from 300 nM to 2 nM in
KD for VEGF) is an optimization of the existing interactions of
bH1.
Favorable entropy change is the hallmark of the dual
interaction of bH1 and bH1-44
To determine the thermodynamic profiles of the high-affinity
dual interaction, we first assessed the overall thermal stability of
the dual specific Fabs by performing thermal denaturation
experiments using differential scanning calorimetry (DSC) (Figure
S5). The melting temperatures (TM) of the dual specific variants as
Fabs (77uC, 76uC, 74uC for bH1, bH1-81 and bH1-44,
respectively) are slightly lower than that of Hercepin Fab (83uC)
[26], but they are within the range of other therapeutic antibodies
[27]. These Fabs are sufficiently stable for the biophysical studies
described below. Further, the two antigen constructs, VEGF8–109
and HER2-ECD, have been shown previously to be suitable for
thermodynamic studies [26,28].
We then determined the enthalpic (DH) contribution to the
interaction between the bH1 Fab variants and VEGF or HER2
using isothermal titration calorimetry (ITC). The antigen binding
affinities of bH1-44 or Herceptin Fabs are too high for accurate
determination by ITC; therefore, we utilized SPR measurements
to determine the dissociation constants (KD). Changes in free
energy (DG) and entropy (DS) upon binding were calculated from
the KD and DH as described in Methods.
Interestingly, the interactions of bH1 with VEGF and HER2
display markedly similar thermodynamic properties (Figure 4,
Figure S6). Both interactions are exothermic (DH=22.4 kcal/
mol as measured at 30uC in phosphate buffer at pH 7.4) and are
predominantly driven by a highly favorable entropy change
(2TDS=26.5 and 28.2 kcal/mol for VEGF and HER2,
respectively). In contrast, Herceptin Fab interaction with HER2
appears to be primarily driven by favorable enthalpy changes
(DH=213.5, 2TDS=0.9 kcal/mol) as determined side-by-side
with bH1 antibodies in this study, which is similar to the values
described previously [26].
The high-affinity interactions of bH1-81 and bH1-44 with
antigens are also characterized by favorable enthalpy and entropy
(Figure 4). For both VEGF and HER2 interactions, the affinity
Figure 2. Antigen-binding affinity and kinetic of the bH1 variants and Herceptin. (A) kon and koff and dissociation constant (KD) of Fabs
binding to immobilized VEGF or HER2 are determined by SPR measurements (See Methods). The errors represent the standard deviations based on at
least three independent experiments. bH1-81 was measured only once. Hence no error estimation is available. NB=No binding detected. ND=Not
determined as the interaction was too weak to assess. The representative binding responses over time of 0.5 mM Fab bH1-44 (red), bH1-44 (LC-Y32)
(green), bH1-44(LC-I29A+Y32A) (magenta) and bH1-44(HC-R50A+R58A) (gray) to immobilized VEGF109 (B) or HER2-ECD (C).
doi:10.1371/journal.pone.0017887.g002
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DH=27.1 (bH1-44) versus 22.4 kcal/mol (bH1) for VEGF;
DH=25.3 (bH1-44) versus 22.4 kcal/mol (bH1) for HER2 at
30uC. Further, the two double mutants of bH1-44 that retain high
affinity for either HER2 (LC-I29A/Y32A) or VEGF (HC-R50A/
R58A) exhibit the same profile of favorable enthalpy and entropy
contributions as bH1-44 (Figure 4). Hence, the contrasting
binding thermodynamics of bH1 antibodies compared to Her-
ceptin is consistently demonstrated in both binding functions of
many bH1 variants.
To further confirm the favorable entropy changes associated
with the interactions of the bH1 antibodies, we determined the
contribution of protonation effects to the observed DH values. For
protein-protein interactions, the measured DH can sometimes
include heat effects related to protonation/deprotonation of the
protein and buffer components. This can lead to inaccuracy in the
calculation of DS for binding. We used the commonly accepted
procedure [29] to examine and correct for these effects. We
measured the enthalpy changes of the bH1-44 and Herceptin
interactions in Tris buffer (pH 7.5) (DHTris), which has a large
ionization enthalpy (DHTrisBuffer=11.1 kcal/mol, 30uC) [30] and
compared these to the values measured in phosphate buffer
(pH 7.4)(DHPBS), which has minimal ionization enthalpy [31]. For
bH1-44 binding to VEGF, no significant difference in DH was
observed in the two buffers, indicating that no significant exchange
of protons occurs between the proteins and the buffer in this
interaction (Table 2). For the Herceptin/HER2 and bH1-44/
HER2 interactions, however, significant differences were ob-
served indicating that protonation of the proteins occurs in
association with HER2 binding. The change in enthalpy
corresponds to approximately 0.5 protons ((DHTris2DHPBS)/
DHTrisBuffer=28.02(213.5)/11.1=0.5) for each Herceptin/
HER2 interaction and 0.2 protons (23.12(25.3)/11.1=0.2) for
each bH1-44/HER2 binding event. Given the pH of the solutions
and the pKa (6.0) of histidine, the most likely scenario is
protonation of one histidine side chain for every two or five
binding events, respectively. Assuming that the enthalpy for
protonation of the histidine is similar as for imidazole (28.7 kcal/
mol, 30uC) [30], the enthalpy change upon binding was cor-
rected by 0.56(28.7)=24.35 kcal/mol for Herceptin and
0.26(28.7)=21.74 kcal/mol for bH1-44. With the correction,
the Herceptin/HER2 interaction is still highly exothermic
DH
corr=29.2 kcal/mol (=213.52(24.35)) and associated with
a small favorable entropy contribution (2TDS
corr=23.4 kcal/
mol, 30uC), whereas the bH1-44 interaction with HER2 is indeed
characterized by a small enthalpy contribution (DH
corr=23.6
kcal/mol (=25.32(21.74)) augmented by a large entropy
contribution (2TDS
corr=29.8 kcal/mol, 30uC)( Table 2).
Hydrophobic interactions drive the binding of bH1
variants and Herceptin
Favorable entropy changes in protein-protein interactions
commonly arise from desolvation, i.e. the hydrophobic effect.
Expulsion of ordered water from the apolar surface upon ligand
binding increases the total entropy of the system. To investigate
the importance of desolvation, we determined the heat capacity
change (DCp) from the temperature dependence of DH for three
interactions: bH1-44 Fab with VEGF or HER2 and Herceptin
Fab with HER2 (Table 2, Figure S7). Highly negative DCp
values were measured for bH1-44/HER2 and bH1-44/VEGF
interactions (Table 2) indicating an important contribution to
binding from the hydrophobic effect (Kauzmann, 1959). The
magnitudes of the DCp values are consistent with the approxi-
mately 60% hydrophobic composition of the interfaces (Table 3),
which is in range of what has been observed in typical protein-
protein or antibody-antigen interfaces. For the Herceptin/HER2
interaction (also ,60% apolar), the previously determined DCp
value of 2370 cal/molK
21 [26] is slightly smaller than the DCp of
bH1-44/HER2 (2440 cal/molK
21), but still indicates the impor-
Figure 4. Thermodynamic profiles of the bH1 variants and
Herceptin. The entropic component (2TDS) and enthalpic component
(DH) of the binding free energy (DG) measured at 30uC in phosphate
buffer (pH 7.4) are shown in kcal/mol. DG was derived from the
dissociation constant (KD) measured with SPR (See Figure 2)
(DG=RTlnKD), and DH was measured using ITC. 2TDS was calculated
from the DG and DH according to 2TDS=DG2DH. Error bars of DG
and DH represent standard deviation of three independent measure-
ments (exception: the enthalpies of the bH1-81/HER2 and bH1-
44(R50A/R58A)/VEGF interactions were measured only once, thus no
error bar), and the errors of 2TDS are combined errors of DG and DH.
doi:10.1371/journal.pone.0017887.g004
Figure 3. Mapping of the evolved dual specific interactions. The changes in binding free energy (DDGmut-wt) when a Fab residue is mutated
to alanine (based on data from Kelley et. al. Biochemistry, 1993, Bostrom et. al., Science, 2009, and the current study) are shown (A). Amino acids are
numbered as in Table 1 and denoted with h or v if making structural contact with HER2 or VEGF (within 4.5 A ˚), respectively, # if mutated from
Herceptin to bH1, and { if mutated from bH1 to bH1-44. Underlined residues are energetically important (DDGmut-wt greater than ,1 kcal/mol, also
underlined) for Herceptin/HER2, bH1-44/HER2 and bH1-44/VEGF interactions indicating importance for all three interactions. Hotspot residues
highlighted in red are those with DDGmut-wt greater than ,10% of the total binding free energy of each interaction. ‘‘-’’ denotes no residue in
Herceptin at the position. Values not determined are left blank. (B) bH1-44 mutations (from bH1) are mapped to locate predominantly outside of
functional hotspots and structural contact for HER2 binding (left) or VEGF binding (right) on the surface of the bH1 paratope modeled with side
chains of bH-44. The residues are colored red if they are bH1 hotspot residues for HER2 or VEGF binding, blue if the residues are mutated from bH1 to
bH1-44 and not part of bH1 hotspot for each respective interaction, or magenta if the mutated residues are part of bH1 hotspot. A mutation is
bolded if the residue is a structural contact site in the respective bH1 interface or underlined if the mutated residue gains significant functional
importance.
doi:10.1371/journal.pone.0017887.g003
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binding. The greater hydrophobic effect in bH1-44 compared to
Herceptin is consistent with a larger buried apolar surface
estimated in the interface of bH1/HER2 complex compared to
Herceptin/HER2 complex (988 versus 910 A ˚ 2, respectively,
Table 3).
Based on the observed DCp, we next calculated the theoretical
apolar surface area buried in the interface (DAnp) as previously
described [26,32]. Large deviations of the calculated buried DAnp
from the observed buried DAnp in the structure of complexes
indicate significant effect of local folding upon binding, e.g.
induced-fit. Examples in the literature include the interaction of a
T cell receptor (TCR) with an antigen peptide-MHC complex
(pMHC) [33] and the TATA binding protein interaction with the
adenovirus E4 promoter [34] where more than 5–16-fold larger
calculated DAnp over the observed DAnp was reported. Small
deviations in the calculated DAnp over the observed DAnp (within
2-fold) are thought to be insignificant, and thus represent a rigid
body interaction [35]. For the Herceptin interaction, the
calculated and the observed buried DAnp in the crystal structure
match closely (DDAnp=30A ˚ 2, 3% of the observed DAnp),
indicating minimal effect of the molecular rearrangements upon
binding, consistent with the small differences between the free and
bound structures of Herceptin and HER2 [23,24] (Figure S2).
For bH1-44, there is also reasonable agreement with the
calculated buried area slightly larger than that observed in the
crystal structure of the bH1 complexes (by 14% and 18%, or
DDAnp=130 A ˚ 2 and 180 A ˚ 2 for VEGF and HER2, respectively).
The small deviations could be due to errors in the determination of
the apolar interfaces based on the crystal structures or the
mutations that distinguish bH1 from bH1-44, and indicate that the
effect of structural rearrangement on the binding of bH1-44 to
either antigen is negligible. Although a structure of free bH1-44 is
not available for calculations of solvent accessible surface area, the
thermodynamic data suggest that no significant refolding of the
CDR loops involving changes in exposure of hydrophobic groups
concurs with antigen binding.
bH1-44 and Herceptin interactions exhibit similar
conformational entropy change
As bH1 exhibits highly distinct conformations in the HER2 and
VEGF complexes, it is possible that the CDR loops are rather
flexible in the unbound state. We therefore examined the extent of
the entropy changes due to the loss of conformational freedom
upon bH1-44/HER2 interaction versus Herceptin/HER2 inter-
action. We dissected the total entropy change observed (DSTOT),
which is comprised of entropy changes from desolvation effects
(DSSOLV), reduction of rotational and translational freedom
(DSRT), and changes in internal conformational freedom (DSCONF)
(DSTOT=DSSOLV+DSRT+DSCONF) [36]. Based on the heat
capacity change (DCp) described above, DSSOLV was calculated
as 96 cal/molK
21 for bH1-44/VEGF, 105 cal/molK
21 for bH1-
44/HER2 and 89 cal/molK
21 for Herceptin/HER2 (Table 2).
DSRT was estimated to contribute 28 cal K
21 mol
21 for all
interactions [36,37], and we derived DSCONF to be 272 cal K
21
mol
21 for bH1-44/VEGF, 264 cal K
21 mol
21 for bH1-44/
HER2, and 270 cal K
21 mol
21 for Herceptin/HER2 (Table 2).
Thus, HER2 binding by Herceptin and bH1-44 involves a similar
conformational entropy penalty. The slightly larger entropic
penalty from reduction in the conformational freedom for the
Table 2. Thermodynamic parameters of Fab interactions with VEGF and HER2.
DHPBS DHTris DH
CORR DSTOT DCp DSCONF DSSOLV DSRT
kcal mol
21 kcal mol
21 kcal mol
21 calK
21 mol
21 calK
21 mol
21 calK
21 mol
21 calK
21 mol
21 calK
21 mol
21
bH1-44/VEGF 27.1 28.0 27.1 16 2400 272 96 28.0
bH1-44/HER2 25.3 23.1 23.6 32 2440 265 105 28.0
Herceptin/HER2 213.5 28.0 29.2 11 2370 270 89 28.0
DGPBS and DGTris were determined by ITC in PBS (pH 7.4) or Tris (pH 7.5) buffer at 30uC.
DG
CORR, corrected DG, was calculated as described in Results.
DSTOT, net total DS, was calculated from DG
CORR and DG as described in Methods.
DCp, heat capacity change, was calculated by linear regression of the temperature versus DH (Figure S6 and Methods). DCp of Herceptin/HER2 (2370 calK
21 mol
21+/
230 calK
21 mol
21) is based on [26]. Standard errors of DCp measurements for bH1-44/VEGF and bH1-44/HER2 interactions are 7 and 13 calK
21 mol
21, respectively.
DSSOLV=DCpln(T/Ts*), where T=303.15 K and Ts*=385.15 K.
DSRT was estimated to 28 cal K
21 mol
21 for a protein binding reaction.
DSCONF was calculated as DSCONF=DSTOT2DSSOLV2DSRT, see Methods.
Standard errors of the ITC measurements were generally within 10% (See Figure 4).
doi:10.1371/journal.pone.0017887.t002
Table 3. The area and property of the interfaces in the Fab/antigen complexes.
Interface bH1/VEGF bH1/HER2 Hercepin/HER2
bH1 VEGF Combined Fraction bH1 HER2 Combined Fraction Herceptin HER2 Combined Fraction
Polar 311 295 606 40% 308 282 591 37% 307 308 614 40%
Apolar 438 462 900 60% 470 518 988 63% 441 469 910 60%
Total 749 757 1506 779 800 1579 747 777 1524
All numbers in A ˚2 unless otherwise indicated.
The polar and apolar area of the interfaces was assessed using XSAE (See Methods). The area was calculated using a probe with a radius of 1.4 A ˚.
doi:10.1371/journal.pone.0017887.t003
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action may reflect what is observed in the crystal structures of free
VEGF showing multiple conformations in the regions bound by
bH1 [38]. The crystal structures of HER2 did not reveal such
structural diversity [22,24]. Thus, compared to the Herceptin/
HER2 interaction, the bH1-44 interactions with HER2 or VEGF
are associated with relatively similar extents of entropic penalty
due to the reduction of conformational freedom.
Temperature dependence of association rate constants
of bH1-44 and Herceptin interactions is similar
We next examined the temperature dependence of the
association rate constants to assess the activation energy for
complex association as described in other studies [35,39,40,41].
The activation energy is a measure of the energy required to reach
the transition state for association or dissociation. Large activation
energy of association has been proposed to result from the
energetic costs of ordering a flexible binding site for interaction
[40]. The activation energy for dissociation on the other hand is
indicative of the degree of complex stabilization.
By examining the binding kinetics of bH1-44 or Herceptin by
SPR measurements at temperatures ranging from 5uCt o3 7 uC, we
found that the associate rate constants (kon) of bH1-44 interaction
with HER2 or VEGF displayed a similar temperature dependence
as Herceptin Fab interaction with HER2, i.e., the slopes of linear
regression of ln kon plotted against 1/T were very similar (linear
coefficient=0.973, 0.998, 0.972, respectively) (Figure S8) (See
Methods). Therefore, the bH1-44 paratope appears similarly
accessible for either HER2 or VEGF binding as the Herceptin
paratope is for HER2 binding. This is consistent with the
conclusion above that bH1-44 and Herceptin interactions are
subjected to similar entropic penalties due to reduction of
conformational flexibility upon antigen binding. The apparent
additional structural plasticity required for the dual interaction of
bH1-44 relative to Herceptin appears to pose minimal additional
energy barriers.
Discussion
Herein, we examined the interactions of bH1 antibodies with
HER2 and VEGF by mutagenesis, structural, biophysical and
thermodynamic studies. Both interactions exhibit properties
characteristic of antibody-antigen interactions: high affinity,
exquisite specificity contributed by a small number of functional
hotspot residues, and the size and properties of the complementary
interfaces. Conventional wisdom expects that the significant
structural plasticity demanded by this dual specificity would result
in a high entropic cost. But that is not what we observed. The bH1
interactions, in contrast to Herceptin interaction, are entropy-
driven. Dissecting the favorable total entropy changes revealed
that the entropic penalty from the reduction of conformational
freedom for bH1-44 upon binding to either antigen is similar to
that for Herceptin, which exhibits only minimal structural
plasticity. Comparing the calculated and observed apolar surface
area buried in the interface indicated that the structural
rearrangement of the bH1-44 paratope concurrent with antigen
binding impacted the binding energy minimally. Thus the distinct
conformations of bH1 antibodies for dual binding appear to be at
a similar energetic state. These conformations may be present
prior to antigen binding as isomers (preexisting equilibrium
mechanism), may appear during the binding interaction through
rearrangement (induced fit mechanism), or a combination of the
two scenarios may occur. Overall, the large desolvation energy or
hydrophobic effect is the common driver for the dual-specific bH1
variants to engage both HER2 and VEGF and plays a more
dominant role in dual interaction than in the Herceptin-HER2
interaction. Recently, Boulanger et al. reported that large
desolvation energy in the absence of any observable plasticity
structurally is the main driver for the recognition of multiple
distinct ligands by the cytokine receptor gp130 [42]. Hence, water
repulsion indeed endows the structure-insensitive entropic energy
that can drive the multi-specific interactions in the absence or in
the presence of apparent structural plasticity.
In the immune system, structural plasticity plays an important
role in the antigen recognition of both antibodies and T cell
receptors (TCR) [43,44] [45,46]. While the antigen binding sites of
antibodies and TCRs have essentially the same fold, they differ in
their antigen binding affinities. TCRs typically have low affinity
(KD in the range of 1–100 mM) for antigen, which is a peptide
fragment loaded major histocompatibility complex (pMHC),
whereas antibodies are often matured to high affinities (in the
nanomolar range). The low affinity TCR-pMHC interactions
often involve structural plasticity of the antigen binding sites that
significantly impacts the binding energetics as manifested by large
conformational entropy penalties, significant local folding effects
(large deviations between the observed and the calculated buried
apolar surface area) and/or large activation energies
[33,40,41,46]. Although the structural plasticity of TCRs contrib-
utes to low affinity it may play an important role for T cells in
distinguishing between MHCs presenting self and non-self
peptides, thus regulating the immune response [33,41]. The low
affinity requirement for TCR function may explain why the
commonly observed structural plasticity for TCR interactions with
their natural ligands rarely associates with positive entropic
contribution. In contrast, the mission of antibodies is to capture
antigens efficiently. The affinities of antibodies are improved by
somatic mutations that can stabilize and fix the free paratope
conformations for antigen binding thereby reducing the entropic
penalty upon binding [47,48]. Here, we show that structural
plasticity of antibodies can occur without large entropic penalties
and allow high affinity antigen binding, suggesting that increasing
the structural plasticity (or adaptability) without increasing the
entropic cost may be a general mechanism for antibody
maturation as well as antibody multi-specificity.
The available structural data have revealed that structural
plasticity is a common and important phenomenon at the site of
molecular interactions [49,50]. Structurally accessible and adapt-
able (plastic) regions of natural proteins often evolve as sites for
ligand interaction [51,52]. Further, structurally plastic regions
have been shown to preferentially attract new binding ligands in
vitro by repertoire selection of non-biased libraries of peptides and
proteins [49,51]. The adaptability of molecular surfaces appears to
play a key role for the capacity for interaction. Our comprehensive
analysis of the high affinity bH1 antibodies reveals how antibody-
antigen interactions characterized by entropy-driven binding
interactions can occur in the presence of significant conforma-
tional plasticity. The combination of these biophysical and
structural properties are likely important not only for bH1, but
also for other antibodies to evolve binding specificity to one or
more antigens and contribute to the vast antibody-antigen
recognition capacity of the antibody repertoire.
Methods
Protein expression, purification and binding analysis
bH1, bH1-81 and bH1-44 antibodies were isolated from phage
displayed antibody libraries and cloned into Fab and IgG
expression vectors, expressed in E. Coli and 293 cells respectively,
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[22]. VEGF8–109 denotes the amino terminus 8–109 amino acids
of the receptor-binding domain of VEGF and was expressed in E.
Coli, purified and refolded as described [53]. The extracellular
domain (ECD) of HER2 was expressed and purified as described
[54]. All proteins were finally dialyzed into phosphate buffer saline
(PBS) or other buffer as specified, and quantified by UV
absorption for characterization.
Affinity measurements and kinetic analysis
To determine the binding kinetics and affinity we performed
an SPR-based assay on a BIAcore 3000. We immobilized
VEGF8–109 and HER2 ECD on CM5 chips at a density that
allowed us to achieve Rmax in the range of 50–150 Response
Units (RU). Serial dilutions of Fab in PBS with 0.05% Tween20
were injected at 30 ml/min. The binding responses were
corrected for buffer effects by subtracting responses from a blank
flow cell. A 1:1 Langmuir fitting model was used to estimate the
kon (on-rate) and koff (off-rate). The KD values were determined
from the ratios of kon and koff.
Temperature dependence of binding kinetics
The binding kinetics was measured at a temperature range of
5uCt o3 7 uC using SPR on a BIAcore3000. The natural logarithm
of the kon or koff was plotted against the inverse of temperature.
The slopes of the line by linear regression were determined. Based
on Arrhenius analysis [55], the energy barrier, or activation energy
(Ea) can be derived from the slopes (Ea=2slope multiplied by R,
R=gas constant). The off-rates for high affinity Herceptin and
bH1-44 at low temperatures were not reliable based on standard
SPR determination, therefore we do not discuss the energy barrier
of dissociation.
Isothermal titration calorimetry
Microcalorimetric measurements of the interaction between
Fabs and human VEGF8–109 and HER2 ECD were performed on
a VP-ITC titration calorimeter (Microcal Inc.) as described [26].
Protein solutions were extensively dialyzed into phosphate-
buffered saline pH 7.4 or 10 mM Tris-HCl pH 7.5. The antigen
and Fabs were dialyzed in the same buffer vessel to minimize
mixing heat effects due to differences in buffer composition. Fabs
at a concentration of 100–220 mM were titrated into antigen
solutions (HER2 ECD or VEGF109) at a concentration of 10–
22 mM. This concentration of antigen was required for precise
enthalpy measurements, but precludes determination of the KD in
cases where the binding affinity was high. 15 or 20 injections were
performed to obtain a 2-fold excess of antibody. The heats of
reaction were determined, heats of Fab dilution were subtracted,
and the DH was calculated. The bH1 was the only variant with an
affinity sufficiently low to be estimated by ITC. The KD was in
good agreement with the values obtained by SPR. For all
antibodies the dissociation constants (KD) determined by surface
plasmon resonance were used to determine the binding free energy
(DG) according to:
DG~RTln KD ðÞ
The binding free energy (DG) and the enthalpy change (DH)
determined by ITC allowed the calculation of the change in
entropy upon association (DS) according to:
DG~DH{TDS
or
DS~ DH{DG ðÞ =T, where T is the temperature in Kelvin K ðÞ
For determination of the heat capacity, DCp, microcalorimetric
measurements were performed as described above at different
temperatures ranging from 20uCt o3 7 uC (293–310uK). The DCp
was determined by linear regression by plotting DH as a function
of the temperature.
Differential scanning calorimetry
Thermal denaturation experiments were performed on a
differential scanning calorimeter from Microcal Inc. Fabs were
dialyzed against 10 mM sodium acetate pH 5, 150 mM sodium
chloride. The solutions were adjusted to a concentration of
0.5 mg/ml and heated to 95uC at a rate of 1uC/min. The melting
profiles were baseline corrected and normalized. The TM was
determined using the software supplied by the manufacturer.
Characterization of the bH1/VEGF and bH1/HER2
structural interface
The biochemical composition of the binding interface was
calculated using the SOLV function in the program XSAE (from
Dr. C. Broger, Hoffmann-La Roche, Basel, Switzerland). This
program calculates the surfaces of selected binding fragments/
chains in structures. The area was calculated using a probe with a
radius of 1.4 A ˚. For each atom the solvent accessible surface area
and the area occluded by atoms of the other chain (both in A ˚ 2) are
calculated. The program designates the occlusions as polar,
hydrophobic or mixed. ‘‘Mixed’’ means occlusion of polar atoms
on one chain by hydrophobic atoms on another chain. We
estimated the buried hydrophobic surface area as the purely
hydrophobic occlusions plus half of the mixed. All structural
figures were generated using Pymol (by W. DeLano).
Construction of bH1-44 and Herceptin mutants
A vector that encoded the Fab fused to the N-terminus of
geneIII via the heavy chain was used as the template for Kunkel
mutagenesis [56]. Oligonucleotides were designed to introduce
the desired alanine mutations at selected positions. The Fab Ala
mutants were expressed as phage and the relative binding affinity
estimated by competition ELISA. The heavy chain and the light
chain variable domains were then cloned into Fab and IgG
expression vectors, and Fabs and IgGs expressed and purified as
described [22]. SDS PAGE verified the correct protein size and
size exclusion chromatography confirmed aggregation levels
below 5%.
Dissection of the entropy change
The total entropy change (DSTOT) can be divided into
contributions from desolvation effects (DSSOLV), entropy changes
from the loss of rotational and translational degree of freedom
(DSRT) and changes in configurational and conformational
flexibility and dynamics of the interacting molecules (DSCONF)
[36]. This can be expressed as:
DSTOT~DSSOLVzDSRTzDSCONF
Typically, only DSSOLV is positive while DSRT and DSCONF are
both negative. DSRT is estimated to contribute 28 cal K
21 mol
21
(the cratic entropy term) for the association of two molecules as
described [36,37]. DSSOLV is dominated by the hydrophobic effect
due to the burial of apolar surface area and can be described as a
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DSSOLV~DS   zDCp ln T=T  ðÞ , where T   ~385 K and DS   *0
DSCONF can thus be estimated as:
DSCONF~DSTOT{DSRT{DSSOLV
Supporting Information
Movie S1 Movie modeling the molecular acrobatics of
CDRs for bH1 dual interaction. The significant structural
plasticity of bH1 is highlighted by morphing between VEGF-
bound bH1 (PDB code 3BDY) and HER2-bound bH1 (PDB
code 3BE1) presented as described in Figure S1. Please note the
highly distinct conformation of CDR-L1, the adjustment of
the side chains of highlighted residues, and the side chains of
LC-I30c and LC-Y32 that alternatively occupy the nearby
cavity in HER2 bound bH1 or VEGF bound bH1, respectively.
The movie (see movie S1) has been generated using the
morphing function of Rigimol which is part of MacPymol 1.3
(www.pymol.org).
(MOV)
Figure S1 The structural plasticity of bH1 CDRs. The
three HC (in blue) and three LC CDRs (in yellow) of bH1 are
shown in cartoon representation with the rest of bH1 structure as
surface of the VEGF bound form. The side chains of selected
residues as in Figure 1 are shown in stick representation. Please see
Movie S1 for the extent of bH1 CDR movements for its dual
binding mode.
(TIF)
Figure S2 Superimposition of Herceptin as Fv and Fab
in their unbound form with HER2-bound Fab shows
small conformational variability. The CDRs of representa-
tive protamers of the Herceptin variable fragment (Fv) (orange,
PDB entry 1FVC) and of the Herceptin Fab (olive and teal, PDB
entry 1FVD) – both in the unbound form – are shown in cartoon
representation. Both structures were superimposed with the
Herceptin Fab bound to the ECD of HER2 (blue, PDB entry
1N8Z). Three different conformations of the CDR-H3 region in
the unbound Herceptin fragments were observed, one of them (in
teal) being similar to the CDR-H3 conformation observed in the
HER2 bound Fab. In the unbound structure, CDR-H3 with
residue Y105 (or Y100a as Kabat numbering) shown in stick
representation is involved in crystal packing explaining the
different conformation of the CDR-H3 loop (Eigenbrot, C. et al.
J. Mol. Biol. 229, 969–995, 1993).
(TIF)
Figure S3 Distinct residues contributing to VEGF- or
HER2-binding. The residues that are important for VEGF
binding LC-I29 and LC-Y32 (A and B) and for HER2 binding
HC-R50 and HC-R58 (C and D) are shown as cyan sticks on the
bH1/VEGF (A and C, 2.6 A ˚ resolution) or bH1/HER2 (B and D,
2.9 A ˚ resolution) crystal structures (Bostrom et. al., Science 323,
p1610, 2009). The residues I29 and Y32 appear to be involved in
intra-chain interactions that serve to maintain the CDR-L1 loop
conformation necessary for VEGF-binding. In the HER2-bH1
structure, I29 is solvent exposed and Y32 packs against HER2 but
does not engage in functionally important interaction. R50 and
R58 pack against D560 and E558 on HER2 and appear to engage
in charge-charge interactions. R50 and R58 are solvent exposed in
the VEGF complex structure.
(TIF)
Figure S4 Herceptin Fab binding to HER2 is severely
disrupted by the same mutations that abolish bH1-44
interaction with HER2. (A) The kinetics of the Fabs binding to
immobilized HER2 was determined using surface plasmon
resonance at 30uC using a 1:1 Langmuir binding fitting model.
Error bar represents the standard deviations (SD) of more than
three independent experiments. NB=No binding detected. (B)
SDS-PAGE of the R50A, R58A and R50A/R58A Herceptin
mutant Fabs (non-reduced). The expressed two-chain Fabs
appear sufficiently folded to associate as covalently linked
heterodimer.
(TIF)
Figure S5 Thermostability of the dual specific Fabs.
bH1 Fab (A), bH1-81 Fab (B), and bH1-44 Fab (C) at 0.5 mg/ml
were heated to 95uC at a rate of 1uC/min. The melting profiles
were baseline corrected and normalized. The black trace
represents the measured melting curve and the red trace the
fitted curve. The melting temperatures (Tm) were calculated from
the fitted curves according to the manufacturer’s instructions to
77uC, 76uC, 74uC for bH1, bH1-81 and bH1-44, respectively.
(TIF)
Figure S6 Representative calorimetric measurements
of the enthalpy changes associated with Fab-antigen
binding at 306C. The individual heat pulses (top) and the heats
of reaction (bottom), which are calculated by integration of each
pulse, are plotted as a function of the antibody to antigen ratio for
each injection. The small magnitude of the enthalpy changes
required relatively high protein concentrations, which precluded
accurate estimation of the KD when the affinity was high.
Solutions of VEGF109 or HER2-ECD at concentrations ranging
from 10–20 mM were titrated by 15 injections of bH1 or bH1-44
Fab at concentrations from 100 to 200 mM in PBS. (E–F) Solutions
of VEGF109 or HER2-ECD at concentrations of 10 to 20 mM
were titrated by 20 injections of bH1-44 LC-I29A+Y32A Fab or
bH1-44 HC-R50A+R58A Fab at concentrations of 150 and
250 mM in PBS. Titrations 1 and 13 in (E) were excluded from the
analysis due to instrument noise.
(TIF)
Figure S7 The heat capacity changes associated with
bH1-44 Fab interactions. DCp was determined from the slope
of the temperature dependence of DH between 20uC and 37uC. In
this range, DCp appears to be independent of T, based on the
linear relationship between DH and T (Linear coefficient
R=0.9991 for bH1-44/HER2, R=0.9989 for bH1-44/VEGF).
(TIF)
Figure S8 Temperature dependence of the association
rate constants (kon). The Arrhenius plots (linear regression of
lnkon versus 1/T ) for bH1-44 interacting with HER2 (open circle),
VEGF (open square) and Herceptin Fab (close circle) interacting
with HER2 are shown, with linear correlation coefficient of 0.973,
0.998, 0.972, respectively. The slopes are used to derive the energy
barrier or activation energy of association, Ea
ass (Ea=2(slope)6R,
R=gas constant). Ea
ass in kcal/mol is denoted.
(TIF)
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